<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Coagulation Disorders | Cardiovascular Pharmacology</title>
    
    <!-- Preconnect for performance -->
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    
    <!-- Google Fonts -->
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <!-- Main Stylesheet -->
    <link rel="stylesheet" href="../styles/main.css">
    
    <!-- MathJax Configuration -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true
        },
        svg: { fontCache: 'global' }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <!-- Skip Link -->
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <!-- Reading Progress Bar -->
    <div class="reading-progress-container" aria-hidden="true">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Theme Toggle -->
    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode" title="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="page-wrapper">
        <!-- Floating Mini-TOC -->
        <aside class="floating-toc" id="floating-toc" aria-label="On this page">
            <div class="floating-toc-header">
                <span class="floating-toc-icon">üìë</span>
                <span>On this page</span>
            </div>
            <nav class="floating-toc-nav">
                <ul class="floating-toc-list">
                    <!-- Populated by JS -->
                </ul>
            </nav>
        </aside>

        <div class="container">
            <article class="document-article" role="main" id="main-content">
                <!-- Top Navigation -->
                <nav class="document-nav" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="../index.html" class="nav-button nav-button--toc" aria-label="Table of Contents">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">Contents</span>
                        </a>
                        
                        <a href="topic-04-ischemic-heart-disease.html" class="nav-button nav-button--prev" aria-label="Previous section">
                            <span class="nav-icon">‚Üê</span>
                            <span class="nav-text">Ischemic Heart Disease</span>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span class="progress-current">05</span>
                                <span class="progress-separator">/</span>
                                <span class="progress-total">06</span>
                            </div>
                            <div class="progress-bar-container" aria-hidden="true">
                                <div class="progress-bar-fill" style="width: 83%;"></div>
                            </div>
                            <span class="progress-label">Coagulation Disorders</span>
                        </div>
                        
                        <a href="topic-06-dyslipidemias.html" class="nav-button nav-button--next" aria-label="Next section">
                            <span class="nav-text">Anti-dyslipidemias</span>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>

                <!-- Breadcrumb -->
                <nav class="breadcrumb" aria-label="Breadcrumb">
                    <ol class="breadcrumb-list">
                        <li class="breadcrumb-item"><a href="../index.html">Home</a></li>
                        <li class="breadcrumb-item"><a href="../index.html">Cardiovascular System</a></li>
                        <li class="breadcrumb-item active" aria-current="page">Drugs used in Coagulation Disorders</li>
                    </ol>
                </nav>

                <!-- Document Header -->
                <header class="document-header">
                    <div class="header-badge">
                        <span class="badge-icon">ü©∏</span>
                        <span class="badge-text">Clinical Pharmacology</span>
                    </div>
                    <h1 class="document-title">Drugs used in Coagulation Disorders</h1>
                    <div class="title-meta">
                        <span class="meta-item">
                            <span class="meta-icon">üë§</span>
                            <span>By Geoffrey</span>
                        </span>
                        <span class="meta-item">
                            <span class="meta-icon">üìÖ</span>
                            <span>$11^{\text {th }}$ November 2024</span>
                        </span>
                    </div>
                </header>

                <!-- Main Content Area -->
                <div class="content-wrapper">
                    
                    <!-- START: introduction -->
                    <section id="introduction" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü©∫</span>
                                Introduction
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Hemostasis is important in clot formation to prevent blood loss.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">However, there can be situations in the body there is formation of unwanted clot (thrombus) within the blood vessels. This is called hypercoagulable state.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Conditions like atherosclerosis, bedridden for long time and major surgeries can lead to hypercoagulable state (clot formation).</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Also, blood may fail to form a clot in disorders like haemophilia A, deficiency of vitamin K which may warrant platelet transfusion or supplement of vitamin-K.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Rudolph Virchow defined three predisposing factors leading to abnormal clot formation within the blood vessels (commonly known as Virchow's triad)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The Virchow's triad consists of; vessel wall injury, altered blood flow and hypercoagulability state.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Drugs acting on hemostasis can act at one of the following points;
                                        <br>¬ª Blood coagulation (fibrin formation)
                                        <br>¬ª Platelet function
                                        <br>¬ª Fibrin removal (fibrinolysis)</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: introduction -->

                    <!-- START: embolus-thrombus -->
                    <section id="embolus-thrombus" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">üîÑ</span>
                                Embolus Vs. Thrombus
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Thrombus- a clot that is adherent to the wall of the blood vessel</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Embolus- a clot floating on blood and can be carried away causing blockage of blood flow.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">A thrombus can detached from the wall of the blood vessel hence becomes an emboli</span>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: embolus-thrombus -->

                    <!-- START: coagulation-cascade -->
                    <section id="coagulation-cascade" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚õìÔ∏è</span>
                                Coagulation Cascade
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Coagulation is conversion of liquid blood to a clot.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">The end results is conversion of soluble fibrinogen to insoluble strands of fibrin.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Blood clotting factors are inactive in blood but when the are activated they are designated by the suffix "a" e.g. VIIa, Xa, Xia, thrombin (IIa) etc.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">When one factor is activated, it catalyses the formation of another factor in larger amount and so on.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Vascular endothelium and antithrombin III are the inhibitors of cascade formation.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">There are two pathways of coagulation cascade; intrinsic pathway and extrinsic pathway.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Intrinsic pathway occurs in the blood vessels while extrinsic occurs when the tissue is injured and is initiated by the tissue factor (prothrombin)</span>
                                </li>
                            </ul>

                            <h3 id="role-of-thrombin">The role of thrombin</h3>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Thrombin (factor IIa) cleaves fibrinogen to form fibrin.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Activates factor XIIIa a fibrinoligase which strengthens fibrin to fibrin linkages.</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">It activates platelet aggregation.</span>
                                </li>
                            </ol>
                        </div>
                    </section>
                    <!-- END: coagulation-cascade -->

                    <!-- START: promoters-inhibitors -->
                    <section id="promoters-inhibitors" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚öñÔ∏è</span>
                                Regulation of Hemostasis
                            </h2>
                        </div>
                        <div class="content-card">
                            <div class="table-wrapper">
                                <div class="table-header">
                                    <span class="table-icon">üìä</span>
                                    <span class="table-caption">Table 48.1 Some substances that promote or inhibit haemostasis</span>
                                </div>
                                <div class="table-container">
                                    <table class="content-table">
                                        <thead>
                                            <tr>
                                                <th>PROMOTERS OF COAGULATION</th>
                                                <th>INHIBITORS OF COAGULATION</th>
                                            </tr>
                                        </thead>
                                        <tbody>
                                            <tr>
                                                <td>Adenosine diphosphate (ADP)</td>
                                                <td>Activated protein C</td>
                                            </tr>
                                            <tr>
                                                <td>Plasminogen activator inhibitor</td>
                                                <td>cAMP</td>
                                            </tr>
                                            <tr>
                                                <td>Thromboplastin</td>
                                                <td>Nitric oxide</td>
                                            </tr>
                                            <tr>
                                                <td>Thromboxane A,</td>
                                                <td>Prostacyclin</td>
                                            </tr>
                                            <tr>
                                                <td>von Willebrand factor</td>
                                                <td>Thrombomodulin</td>
                                            </tr>
                                            <tr>
                                                <td></td>
                                                <td>Tissue plasminogen activator (t-PA)</td>
                                            </tr>
                                        </tbody>
                                    </table>
                                </div>
                            </div>

                            <h3 id="coagulation-defects">Coagulation Defects</h3>
                            <ol class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Deficiency of coagulation factors i.e haemophilia A (deficiency of factor VIII) and hemophilia B (lack of factor IX, chrismas factor)</span>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content">Acquired clotting defects- liver disease, vitamin K deficiency, excessive anticoagulant therapy</span>
                                </li>
                            </ol>
                        </div>
                    </section>
                    <!-- END: promoters-inhibitors -->

                    <!-- START: pathways-drugs -->
                    <section id="pathways-drugs" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõ£Ô∏è</span>
                                Pathways and Drugs
                            </h2>
                        </div>
                        <div class="content-card">
                            <figure class="content-figure" data-lightbox="true">
                                <div class="figure-image-wrapper">
                                    <img src="../../../../assets/images/image-20251214-ace3eea7.jpeg" 
                                         alt="Drugs used in coagulation defects" 
                                         class="figure-image"
                                         loading="lazy">
                                    <div class="figure-overlay">
                                        <span class="overlay-icon">üîç</span>
                                        <span class="overlay-text">Click to enlarge</span>
                                    </div>
                                </div>
                                <figcaption class="figure-caption">Drugs used in coagulation Defects</figcaption>
                            </figure>

                            <h3 id="intrinsic-pathway">INTRINSIC PATHWAY</h3>
                            <h4 id="extrinsic-pathway">EXTRINSIC PATHWAY</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Platelets cling and their surfaces provide sites for mobilisation of factors</strong></span>
                                    <ul class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>XII</strong> -> Activated XII (XIIa)</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>XI</strong> -> Activated XI (XIa)</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>IX</strong> -> Activated IX (IXa)</span></li>
                                    </ul>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Platelet phospholipids released by aggravated platelets</strong></span>
                                    <ul class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Warfarin</strong> -> <strong>IX</strong> -> <strong>VII complex</strong></span></li>
                                    </ul>
                                </li>
                            </ul>

                            <h4 id="common-pathway">COMMON PATHWAY</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Warfarin</strong></span>
                                    <ul class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>X</strong> -> Ca<sup>2+</sup></span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>V</strong> -> Tissue thromboplastin (III) or platelet phospholipids</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">**Ca<sup>2+</sup></span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>V</strong> -> <strong>V</strong> -> <strong>V</strong></span></li>
                                    </ul>
                                </li>
                            </ul>

                            <h4 id="lmwh">LMWH</h4>
                            <ul class="enhanced-list">
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Heparin</strong></span>
                                    <ul class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Fondaparinux</strong> -> Heparin -> <strong>Prothrombin activator</strong> -> <strong>Prothrombin inhibitor</strong> -> <strong>Prothrombin inhibitor</strong></span></li>
                                    </ul>
                                </li>
                                <li class="list-item">
                                    <span class="list-marker"></span>
                                    <span class="list-content"><strong>Warfarin</strong></span>
                                    <ul class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content"><strong>Prothrombin (II)</strong> -> Fibrin -> <strong>Fibrinogen (I)</strong> -> <strong>Fibrinogen (II)</strong> -> <strong>Fibrinogen (III)</strong> -> <strong>Fibrinogen (IV)</strong> -> <strong>Fibrinogen (V)</strong></span></li>
                                    </ul>
                                </li>
                            </ul>
                            <p><strong>Plasmin</strong> - <strong>dissolves</strong> - <strong>Cross-linked fibrin polymer</strong></p>
                        </div>
                    </section>
                    <!-- END: pathways-drugs -->

                    <!-- START: specific-agents -->
                    <section id="specific-agents" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Specific Pharmacological Agents
                            </h2>
                        </div>
                        
                        <div class="content-card">
                            <h3 id="vitamin-k">1. Vitamin K</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">K stands for Koagulation in German</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Fat-soluble vitamin</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Essential for formation of clotting factor II, VII, IX and X.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Pharmacokinetics; naturally occurring vitamin K1(Phytomenadione) is given orally or by injection.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Vitamin K requires bile salts for absorption.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Synthetic vitamin K (menadiol sodium phosphate) it is water soluble therefore, do not require bile salts for absorption.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Synthetic vitamin K takes long to act that the natural one.</span></li>
                            </ul>

                            <h4 id="clinical-use-vit-k">Clinical use of Vitamin K</h4>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Treatment and/or prevention of bleeding like excessive oral anticoagulant like warfarin, hemorrhagic disease of the newborn</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Vitamin K deficiencies- obstructive jaundice, coeliac disease, steatorrhea.</span></li>
                            </ol>

                            <h4 id="side-effects-vit-k">Side effects of vitamin K</h4>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Hypersensitivity reactions</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Skin reaction</span></li>
                            </ol>

                            <h3 id="tranexamic-acid">2. Tranexamic acid & Aminocaproic acid</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Used in fibrinolysis disorders</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Control bleeding</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Active orally, excreted in urine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibit plasminogen activation</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Tranexamic acid is 10 times potent than aminocaproic acid.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Side effect; intravascular thrombosis</span></li>
                            </ul>

                            <h3 id="protamine-sulfate">3. Protamine sulfate</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Derived from fish sperms or testes.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Rich in arginine</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Antagonizes effects of anticoagulant heparin.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The positively charged protamine interacts with negative charged heparin.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Side effects; hypersensitivity reaction, bradycardia, hypotension, dyspnea, flushing</span></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: specific-agents -->

                    <!-- START: platelet-inhibitors -->
                    <section id="platelet-inhibitors" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">07</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõë</span>
                                Platelet Aggregation Inhibitors
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Decrease formation of platelet-rich clot. Or,</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Decrease the chemical signals that activate platelet aggregation.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Adding different agents from different classes adds synergistic effects of these drugs.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Used to prevent occlusive cardiovascular disease and thrombolytic therapy.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">These agents act at the following sites;</span>
                                    <ol class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibit cyclooxygenase 1(COX-1) enzyme</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Block glycoprotein IIb and IIIa</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Block adenosine diphosphate receptors (ADP).</span></li>
                                    </ol>
                                </li>
                            </ul>

                            <h3 id="aspirin">1. Aspirin</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">M.O.A- inhibits thromboxane A2 synthesis by acetylation of a serine residue on the active site of COX-1 hence irreversibly inhibiting the enzyme.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The chemical mediators are shifted to favor antiaggregatory effects of prostacyclin hence prevents platelet aggregation.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Aspirin is the only antiplatelet agent that irreversibly inhibit platelet function.</span></li>
                            </ul>

                            <h4 id="aspirin-therapeutic-use">Therapeutic use of Aspirin</h4>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Prophylactic treatment of transient ischemia</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce incidence of recurrent MI.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Reduce mortality in primary and secondary prevention of MI.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Recommend dose is $50-352 \mathrm{mg}$ daily.</span></li>
                            </ol>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Pharmacokinetics; given orally, absorbed by passive diffusion, hydrolyzed into salicyclic acid in the liver.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Salicyclic further is metabolized in the liver and excreted unchanged in urine.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Half-life of aspirin is 15-20minutes, salicyclic acid is 3-12hrs.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Unwanted effects; increases incidence of haemorrhagic stroke, GI bleeding</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Drug interactions; Ibuprofen block the action of aspirin compete for the same enzyme. Give aspirin 60 minutes before or 8 hrs after administration of ibuprofen.</span></li>
                            </ul>

                            <h3 id="p2y12-inhibitors">Ticlopidine, Clopidogrel, prasugrel & ticagrelor</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">P2Y12 ADP receptor inhibitors</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Block platelet aggregation</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Mechanism of action different from aspirin</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">M.O.A- inhibit binding of ADP to its receptors on the platelets therefore, inhibit activation of GP IIb and IIIa.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Hence this blocks platelets from binding to fibrinogen.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Ticagrelor binds to P2Y12 ADP receptors reversibly but others bind irreversibly.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Clopidogrel inhibit platelet function 3-5 days.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Therapeutic uses; prevent atherosclerosis, prophylaxis of thrombotic events, cerebral transient ischemic attack (TIA)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Pharmacokinetics; require loading dose for quicker antiplatelet effects, extensively bound to plasma proteins, ticlopidine absorption impaired by food.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Metabolized in the liver by cytochrome P450 (CPY), elimination is through the renal and fecal route.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Drug interactions; don't give clopidogrel with omeprazole and esomeprazole concurrently.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Side effects; agranulocytosis, thrombotic thrombocytopenic purpura (TTP), aplastic anaemia, neutropenea, clopidogrel has few side effects</span></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: platelet-inhibitors -->

                    <!-- START: indirect-thrombin-inhibitors -->
                    <section id="indirect-thrombin-inhibitors" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">08</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíâ</span>
                                Indirect Thrombin Inhibitors
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Exert their effect through anti-thrombin protein to prevent clot formation.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Example;</span>
                                    <ol class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Unfractionated heparin (high-molecular weight)</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Low molecular heparin</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Fondaparinux</span></li>
                                    </ol>
                                </li>
                            </ul>

                            <h3 id="heparin">Heparin</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Heterogeneous mixture of sulfated mucopolysaccharides.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Binds to endothelial cell surface and a variety of plasma proteins.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Depends on anti-thrombin protein for its action.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Anti-thrombin inhibits factor IIa, IXa and Xa to stop clot formation.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The active heparin binds tightly to anti-thrombin and causes a conformational change in this inhibitor.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Heparin functions as a cofactor for antithrobin-protease reaction without being consumed.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">High molecular weigh Heparin has high affinity for antithrombin inactivating all the 3 clotting factors.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The low molecular heparin inhibit activated factor X but has less effect on the thrombin.</span></li>
                            </ul>

                            <h4 id="heparin-monitoring">Monitoring of Heparin</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Close monitoring of heparin is essential due to its adverse effects.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Heparin is monitored by use of activated partial thromboplastin time (aPTT or PTT)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">The common monitored is unfractionated heparin (UFH).</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">LMW-heparin is not monitored unless in patients who have renal insufficiency, obesity and pregnancy.</span></li>
                            </ul>

                            <h4 id="heparin-toxicity">Toxicity of Heparin</h4>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Bleeding - heparin needs close monitoring</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Allergy- heparin is of animal origin (bovine)</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Osteoporosis- pathological fractures in long term use</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Loss of hair and reversible alopecia.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Accelerates clearance of postprandial lipemia through release of lipoprotein lipase from tissues.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Mineralocorticoid deficiency in long term use.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Heparin induced thrombocytopenia- systemic hypercoagulable state (thrombus formation). Treatment; stop heparin, administer direct thrombin inhibitor.</span></li>
                            </ol>

                            <div class="collapsible-section">
                                <details class="collapsible-section">
                                    <summary class="collapsible-trigger">
                                        <span class="trigger-icon">‚ö†Ô∏è</span>
                                        <span class="trigger-text">Contraindications of Heparin</span>
                                    </summary>
                                    <div class="collapsible-content">
                                        <p>(1) Patients who recently had surgery of the brain, spinal cord, eye</p>
                                        <p>(2) Lumber puncture patients</p>
                                        <p>(3) Thrombocytopenia</p>
                                        <p>(4) Hemophilia A</p>
                                        <p>(5) Heparin induced thrombocytopenia (HIT)</p>
                                        <p>(6) Allergic reaction to heparin</p>
                                        <p>(7) Severe hypertension</p>
                                        <p>8. Purpura</p>
                                        <p>9. Infective endocarditis</p>
                                        <p>10. Active tuberculosis</p>
                                        <p>11. Threatened abortion</p>
                                        <p>12. Visceral carcinoma</p>
                                        <p>13. GIT ulcers</p>
                                        <p>14. Renal or liver insufficiency</p>
                                    </div>
                                </details>
                            </div>

                            <h4 id="heparin-administration">Administration & Dosage</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Before administration of heparin, do baseline PT &amp; aPTT.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inquire about any bleeding tendencies from the patient.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Do aPTT 6 hours after administration of UFH.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">LMW-heparin is preferred because there is no monitoring required.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Can be given through infusion or subcutaneous injection.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Never administer heparin intramuscularly - hematoma formation.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Dosage; 5000 units 8-12 hours subcutaneous injections</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Prophylactic enoxaparin 30mg BD or 4 omg OD</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Fondaparinux is dosed once daily.</span></li>
                            </ul>

                            <h4 id="heparin-reversal">Reversal of Heparin</h4>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Discontinue the heparin if bleeding occurs.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Excessive bleeding give antagonist protamine sulfate</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">For every 100 units of heparin remaining in the patient, give intravenously 1 mg of protamine sulfate.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Avoid excessive administration of protamine sulfate!!</span></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: indirect-thrombin-inhibitors -->

                    <!-- START: rivaroxaban -->
                    <section id="rivaroxaban" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">09</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Rivaroxaban
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Oral anti-thrombin agent that inhibit the formation of fibrin.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Used in treatment of thromboembolic disease</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">It selectively inhibit factor Xa in the coagulation cascade.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Inhibition of factor Xa prevents conversion of prothrombin to thrombin hence disrupt clot formation.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Side effects; gastrointestinal upset, anemia, hemorrhage, muscle cramping and syncope.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Uses- thromboembolism, thromboprophylaxis</span></li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: rivaroxaban -->

                    <!-- START: warfarin -->
                    <section id="warfarin" class="content-section">
                        <div class="section-header">
                            <div class="section-number" aria-hidden="true">10</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß™</span>
                                Warfarin
                            </h2>
                        </div>
                        <div class="content-card">
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Coumarin anticoagulant.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Antagonize cofactor vitamin K.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Monitored by international normalized ratio (INR).</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Has narrow therapeutic index therefore, INR should be maintained at optimal range as possible.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Recommended INR is between 2-3.</span></li>
                            </ul>

                            <h3 id="warfarin-moa">M.O.A of Warfarin</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Factors II, VII, IX &amp; X requires vitamin K as a cofactor for synthesis in the liver.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Warfarin inhibit vitamin K epoxide reductase enzyme preventing regeneration of vitamin K.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Peak effects of warfarin is 72-96 hours. This is the time required to deplete the circulating pool of clotting factors.</span></li>
                            </ul>

                            <h3 id="warfarin-pharmacokinetics">Pharmacokinetic</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Well absorbed after oral administration</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Bound to plasma albumin hence do not cross into the BBB, breast milk and urine.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Drugs like sulfonamides can displace warfarin from plasma due to their greatest affinity to bind to plasma albumin.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Warfarin is metabolized by CYP450 isoenzymes therefore, some drugs can block its metabolism leading to ineffectiveness of this drug.</span></li>
                            </ul>

                            <h3 id="warfarin-uses">Therapeutic use of Warfarin</h3>
                            <ol class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Prevention and treatment of DVT &amp; PTE.</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Stroke prevention</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Prosthetic heart valves</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Protein C and S deficiency</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Antiphospholipid syndrome</span></li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Prevention of DVT formation in major surgeries like orthopedic or gynecological.</span></li>
                            </ol>

                            <h3 id="warfarin-adverse">Adverse Effects of Warfarin</h3>
                            <p>(1) Hemorrhage- stop the drug, give vitamin K</p>
                            <p>(2) Skin lesions</p>
                            <p>(3) Necrosis</p>
                            <p>(4) Purple toe syndrome</p>
                            <p>(5) Warfarin is teratogenic should not used in pregnancy.</p>

                            <h3 id="drugs-interactions">Drugs Interactions</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Those drugs that potentiate;</span>
                                    <ol class="enhanced-list" style="margin-left: 20px;">
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Amiadorone</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Acute alcohol intoxication</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Fluconazole</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Metronidazole</span></li>
                                        <li class="list-item"><span class="list-marker"></span><span class="list-content">Sulfonamides</span></li>
                                    </ol>
                                </li>
                                <li class="list-item"><span class="list-marker"></span><span class="list-content">Those that cause attenuation;</span>
                                    <p>1 Barbiturates</p>
                                    <p>2 Chronic alcohol ingestion</p>
                                    <p>3 Dicloxacillin</p>
                                    <p>4 Rifampin</p>
                                </li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: warfarin -->

             

                    <!-- Key Points Section -->
                    <aside class="key-points-section" role="region" aria-labelledby="key-points-title">
                        <div class="key-points-wrapper">
                            <div class="key-points-header">
                                <span class="key-points-icon">‚≠ê</span>
                                <h3 id="key-points-title" class="key-points-title">Key Points</h3>
                            </div>
                            <ul class="key-points-list">
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Aspirin is the only antiplatelet agent that irreversibly inhibit platelet function.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Heparin functions as a cofactor for antithrobin-protease reaction without being consumed.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Warfarin inhibit vitamin K epoxide reductase enzyme preventing regeneration of vitamin K.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Never administer heparin intramuscularly - hematoma formation.</strong></p>
                                </li>
                                <li class="key-point-item">
                                    <span class="point-marker">‚úì</span>
                                    <p><strong>Warfarin is teratogenic should not used in pregnancy.</strong></p>
                                </li>
                            </ul>
                        </div>
                    </aside>
                </div>

                <!-- Bottom Navigation -->
                <nav class="document-nav document-nav--bottom" role="navigation" aria-label="Document navigation">
                    <div class="nav-container">
                        <a href="topic-04-ischemic-heart-disease.html" class="nav-button nav-button--prev nav-button--large">
                            <span class="nav-icon">‚Üê</span>
                            <div class="nav-content">
                                <span class="nav-label">Previous</span>
                                <span class="nav-title">Ischemic Heart Disease</span>
                            </div>
                        </a>
                        
                        <a href="../index.html" class="nav-button nav-button--toc">
                            <span class="nav-icon">üìö</span>
                            <span class="nav-text">All Topics</span>
                        </a>
                        
                        <a href="topic-06-dyslipidemias.html" class="nav-button nav-button--next nav-button--large">
                            <div class="nav-content">
                                <span class="nav-label">Next</span>
                                <span class="nav-title">Anti-dyslipidemias</span>
                            </div>
                            <span class="nav-icon">‚Üí</span>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <!-- Scripts -->
    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>